Access cutting-edge crohn's disease treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access crohn's disease specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related crohn's disease treatment provided free
Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in certain other studies for CD or UC (called a parent study) may be able to join this study. The goals of this study are to learn about the safety of tulisokibart over time in people with CD or UC, and i
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this crohn's disease clinical trial in New York, NY
If you're searching for crohn's disease treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced crohn's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.